| reverse passive haemagglutination | If antibodies are bonded to the surface of red blood cells haemagglutination will occur if the appropriate bi or multivalent antigen is added in soluble or microparticulate form. Used as a test for for example Hepatitis B virus in the serum. (18 Nov 1997) |
|---|---|
| reverse pulmonary oedema pattern | <radiology> Loeffler pneumonia, chronic eosinophilic pneumonia (12 Dec 1998) |
| reverse transcription | <molecular biology> The process of copying information found in RNA into DNA. (09 Oct 1997) |
| reverse transcriptons | An enzyme that converts RNA to DNA. Some viruses have only RNA as their primary genetic material. By converting their RNA genes to DNA with this enzyme, the host cell is 'tricked' into creating new copies of the virus. Useful in genetic engineering to make DNA from mRNA. (14 Nov 1997) |
| reverse Trendelenburg position | Supine position without flexing or extending, in which the head is higher than the feet. (05 Mar 2000) |
| DNA reverse gyrase | <enzyme> A topoisomerase II subclass which introduces positive superhelical turns into DNA Registry number: EC 3.1.- Synonym: reverse gyrase (26 Jun 1999) |
| triiodothyronine, reverse | <chemical> 0-(4-hydroxy-3,5-diiodophenyl)-3-iodo-l-tyrosine. A metabolite of thyroxine formed by the peripheral degradation of thyroxine as a result of the tyrosyl or inner ring 5-deiodination. In systemic disease states or in neonates, levels of triiodothyronine are low and those of reverse triiodothyronine are elevated. Reverse t3 is therefore useful as a diagnostic aid and in the treatment of foetal and infantile hypothyroidism. Chemical name: L-Tyrosine, O-(4-hydroxy-3,5-diiodophenyl)-3-iodo- (12 Dec 1998) |
| adrenergic uptake inhibitors | Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (antidepressive agents, tricyclic) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin. (12 Dec 1998) |
| blood coagulation factor inhibitors | Substances, usually endogenous, that act as inhibitors of blood coagulation. They may affect one or multiple enzymes throughout the process. As a group, they also inhibit enzymes involved in processes other than blood coagulation, such as those from the complement system, fibrinolytic enzyme system, blood cells, and bacteria. (12 Dec 1998) |
| Bowman Birk protease inhibitors | <pharmacology> Family of serine protease inhibitors found in seeds of leguminous plants and cereals. (18 Nov 1997) |
| carbonic anhydrase inhibitors | A class of compounds that reduces the secretion of h+ ions by the proximal kidney tubule through inhibition of carbonic anhydrase (carbonate dehydratase). Although their therapeutic use as diuretics is not frequent, they are used in clinical conditions where alkalinization of the urine is beneficial. Their most frequent application is in the reduction of intra-ocular pressure in the treatment of glaucoma. (12 Dec 1998) |
| growth inhibitors | Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth (= plant growth regulators). (12 Dec 1998) |
| phosphodiesterase inhibitors | Compounds which inhibit or antagonise the biosynthesis or actions of phosphodiesterases. (12 Dec 1998) |
| monoamine oxidase inhibitors | A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. Although mao inhibitors are probably as effective as tricyclic antidepressants in the treatment of major depression, the complex, sometimes severe, and often unpredictable interactions between mao inhibitors and many other drugs and food-derived amines make their medical use difficult and potentially hazardous. (12 Dec 1998) |
| platelet aggregation inhibitors | Drugs or agents which antagonise or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system. (12 Dec 1998) |